Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced May 14, 2024
FAILED TRIAL: Ph 3 CheckMate -73L trial did not meet primary endpoint of PFS in unresectable, locally advanced stage III NSCLC May 14, 2024
FAILED TRIAL: Pivotal Ph 3 Study of Uproleselan in R/R AML patients did not meet primary endpoint of OS in the intent-to-treat population May 14, 2024
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of XCE853 May 14, 2024
Kite and Arcellx share design of global Ph 3 trial, iMMagine-3, to evaluate anito-cel in patients exposed to both an lMiD drug and an anti-CD38 mAb May 14, 2024
Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK to Conduct a Ph 2 Randomized Trial in Early-Stage Breast Cancer in Europe for INT230-6 May 14, 2024
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer May 14, 2024
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
FDA clears IND application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors May 14, 2024
China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors May 14, 2024
